TherapeuticsMD analyst ratings
TherapeuticsMD analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2022 | -87.91% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 20.92% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -87.91% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -69.77% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -63.72% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -85.49% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -39.54% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 81.38% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -27.45% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 226.48% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 33.01% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -27.45% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 20.92% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/13/2022 | -87.91% | 坎託·菲茨傑拉德 | → 1 美元 | 重申 | → 中立 |
| 2022 年 7 月 6 日 | 20.92% | HC Wainwright & Co. | → 10 美元 | 降級 | 買入 → 中性 |
| 2022 年 6 月 5 日 | -87.91% | 坎託·菲茨傑拉德 | 5 美元 → 1 美元 | 降級 | 超重 → 中性 |
| 03/11/2022 | -69.77% | HC Wainwright & Co. | $3 → 2.5 美元 | 維護 | 購買 |
| 11/12/2021 | -63.72% | HC Wainwright & Co. | 4 美元 → 3 美元 | 維護 | 購買 |
| 08/07/2020 | -85.49% | 傑富瑞集團 | 1.25 美元 → 1.2 美元 | 降級 | 持有 → 表現不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 05/07/2020 | -39.54% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 購買 |
| 2020 年 4 月 16 日 | 81.38% | Stifel | 14 美元 → 15 美元 | 維護 | 購買 |
| 02/21/2020 | -27.45% | HC Wainwright & Co. | 7 美元 → 6 美元 | 維護 | 購買 |
| 08/14/2018 | 226.48% | 坎託·菲茨傑拉德 | 26 美元 → 27 美元 | 維護 | 超重 |
| 06/15/2018 | 33.01% | 摩根大通 | → 11 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 09/08/2017 | -27.45% | 摩根士丹利 | → 6 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 2017 年 7 月 21 日 | 20.92% | 德意志銀行 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
TherapeuticsMD Questions & Answers
TherapeuticsMD 問題與解答
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on July 13, 2022. The analyst firm set a price target for $1.00 expecting TXMD to fall to within 12 months (a possible -87.91% downside). 5 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年7月13日公佈了TherapeuticSMD（納斯達克股票代碼：TXMD）的最新目標股價。該分析公司將目標股價設定爲1.00美元，預計TXMD將在12個月內跌至-87.91％（可能下跌-87.91％）。去年有5家分析公司公佈了評級。
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
TherapeuticSMD（納斯達克股票代碼：TXMD）的最新分析師評級由坎託·菲茨傑拉德提供，TherapeuticsMD重申了他們的中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on July 13, 2022 so you should expect the next rating to be made available sometime around July 13, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與TherapeuticsMD的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。TherapeuticsMD的最後一次評級是在2022年7月13日提交的，因此您應該預計下一個評級將在2023年7月13日左右公佈。
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $1.00. The current price TherapeuticsMD (TXMD) is trading at is $8.27, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的TherapeuticsMD（TXMD）評級得到了重申，目標股價爲0.00美元至1.00美元。TherapeuticSMD（TXMD）目前的交易價格爲8.27美元，超出了分析師的預期區間。